Imprimis Pharma (IMMY) Reports Q1 Revenues Above Estimates

Imprimis Pharma (NASDAQ: IMMY) reported Q1 EPS of $, versus $0.00 reported last year. Revenue for the quarter came in at $8.9 million versus the consensus estimate of $6.86 million.

Notable Highlights:

• Revenue of $8.9 million, up 45% year-over-year
• Gross ophthalmology-related revenue of $7.0 million, up 91% year-over-year
• Gross Margin of 54%, compared to 45% in Q1 2017
• Adjusted EBITDA loss (a non-GAAP measure) of $431,000, an 85% improvement year-over-year, and 46% improvement quarter-over-quarter
• First month of Adjusted EBITDA profitability in March
• 16 straight quarters of double digit or better year-over-year revenue growth
• Eton Pharmaceuticals filed its first new drug application (NDA) with the US Food and Drug Administration, advanced programs that are expected to result in additional NDA filings over the next 12 months, and increased active drug development programs from four to eight
• Surface Pharmaceuticals announced a $20 million Series A financing at $3.30 per share with Flying L Partners, a premier ophthalmology-focused investor with a strong track record of success

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c